Skip to content
drillr.ai
Sign up

VSTM

Verastem, Inc.

NASDAQ · Healthcare · Biotechnology · US

$8.20
+2.76%
Ask drillr

  • Aug 7, 2026, 00:00 UTC

    Verastem, Inc. amended its Note Purchase Agreement on August 6, 2026, restructuring existing notes and adding a new series of up to $75 million in revenue-based notes.

  • Aug 6, 2026, 22:40 UTC

    Verastem reported a second-quarter loss of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 and improving from a loss of $0.39 per share a year earlier.

    Source:

  • Jun 17, 2026, 16:45 UTC

    Verastem announced positive updated results from its RAMP 205 trial evaluating its drug combination for metastatic pancreatic cancer.

    Source:

  • Jun 3, 2026, 20:01 UTC

    The U.S. FDA granted Fast Track Designation to Verastem Oncology's investigational drug VS-7375 for the treatment of KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer.